ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP

 
• By Joseph Haas

Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.

PrEp tablet. Vector pre-exposure prophylaxis blue pill developed to prevent HIV epidemic.
ViiV hopes it will join Gilead in the HIV PrEP space with cabotegravir

More from Approval Standards

More from Pathways & Standards